Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery

Preliminary results from NIH clinical trial published

Newswise — WHAT:

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The randomized, controlled trial enrolled hospitalized adults with COVID-19 with evidence of lower respiratory tract involvement (generally moderate to severe disease). Investigators found that remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen. Findings about benefits in other patient subgroups were less conclusive in this preliminary analysis.

The study began on Feb. 21, 2020 and enrolled 1,063 participants in 10 countries in 58 days. Patients provided informed consent to participate in the trial and were randomly assigned to receive local standard care and a 10-day course of the antiviral remdesivir intravenously, developed by Gilead Sciences, Inc., or local standard care and a placebo. The trial was double-blind, meaning neither investigators nor participants knew who was receiving remdesivir or placebo.

The trial closed to enrollment on April 19, 2020. On April 27, 2020 (while participant follow-up was still ongoing), an independent data and safety monitoring board overseeing the trial reviewed data and shared their preliminary analysis with NIAID. NIAID quickly made the primary results of the study public due to the implications for both patients currently in the study and for public health. The report published today in The New England Journal of Medicine describes the preliminary results of the trial.

The report notes that patients who received remdesivir had a shorter time to recovery than those who received placebo. The study defined recovery as being discharged from the hospital or being medically stable enough to be discharged from the hospital. The median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. The findings are statistically significant and are based on an analysis of 1059 participants (538 who received remdesivir and 521 who received placebo). Clinicians tracked patients' clinical status daily using an eight-point ordinal scale ranging from fully recovered to death. Investigators also compared clinical status between the study arms on day 15 and found that the odds of improvement in the ordinal scale were higher in the remdesivir arm than in the placebo arm. Trial results also suggested a survival benefit, with a 14-day mortality rate of 7.1% for the group receiving remdesivir versus 11.9% for the placebo group; however, the difference in mortality was not statistically significant.

Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with COVID-19 and requiring supplemental oxygen therapy, according to the authors. However, they note that the mortality rate of 7.1% at 14 days in the remdesivir arm indicates the need to evaluate antivirals with other therapeutic agents to continue to improve clinical outcomes for patients with COVID-19. On May 8, 2020, NIAID began a clinical trial (known as ACTT 2) evaluating remdesivir in combination with the anti-inflammatory drug baricitinib compared with remdesivir alone.

###

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 2911
Newswise: Obesity a Major Risk for Severe COVID-19 Cases
Released: 13-Aug-2020 4:55 PM EDT
Obesity a Major Risk for Severe COVID-19 Cases
Hackensack Meridian Health

While the U.S. Centers for Disease Control and Prevention (CDC) advises that people of any age can contract COVID-19, obesity has emerged among the major risk factors for severe cases. With more than 40 percent of Americans classified as obese, experts caution that this is a growing concern.

Newswise: Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
Released: 13-Aug-2020 4:10 PM EDT
Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
American Academy of Ophthalmology (AAO)

The American Academy of Ophthalmology shares back-to-online school checklist to protect kids’ eyes from too much screen time.

Newswise: 240042_web.jpg
Released: 13-Aug-2020 3:05 PM EDT
A quick, cost-effective method to track the spread of COVID-19
Hokkaido University

A group of researchers have demonstrated that, from seven methods commonly used to test for viruses in untreated wastewater, an adsorption-extraction technique can most efficiently detect SARS-CoV-2. This gives us another tool to detect the presence and spread of the COVID-19 pandemic.

Released: 13-Aug-2020 2:40 PM EDT
Technion’s Nanofiber PPE Sticker Now In Mass Production
American Technion Society

The COVID-busting ‘Maya’ sticker developed by Technion researchers has gone into mass production. Comprised of a nanofiber sheet, the unique sticker can be easily adhered to a protective mask, significantly improving its effectiveness against the novel coronavirus.

13-Aug-2020 11:00 AM EDT
Massive, rapid vaccine production will require firms to share information
University of Michigan

As the world rushes to identify safe and effective vaccines and therapeutics to counter the COVID-19 epidemic, attention is turning to the next step: manufacturing these products at enormous scale.

Released: 13-Aug-2020 1:05 PM EDT
Additive Manufacturing for COVID-19
Materials Research Society (MRS)

A new Prospective article—Additive Manufacturing for COVID-19: Devices, Materials, Prospects and Challenges—published in MRS Communications, looks at these critical supply issues and provides an overview of 3D printing and how coupling the tools in additive manufacturing (AM) and advanced materials has provided a viable alternative for rapid production and distribution of PPEs and medical devices.

Newswise: Busting Up the Infection Cycle of Hepatitis B
Released: 13-Aug-2020 12:50 PM EDT
Busting Up the Infection Cycle of Hepatitis B
University of Delaware

Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the “spiky ball” that encloses the virus’s genetic blueprint. They examined how the capsid—a protein shell that protects the blueprint and also drives the delivery of it to infect a host cell—assembles itself. Scientists believe that the capsid is an important target in developing drugs to treat hepatitis B, a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Newswise: 240097_web.jpg
Released: 13-Aug-2020 12:05 PM EDT
Stay-at-home orders significantly associated with reduced spread of COVID-19, study finds
Brown University

Across the globe, COVID-19 has infected more than 18 million people to date and has killed hundreds of thousands -- and the United States has been hit especially hard.

Released: 13-Aug-2020 11:45 AM EDT
COVID-19 Symptom Tracker Ensures Privacy During Isolation
Georgetown University Medical Center

An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person’s confidentiality while being able to actively monitor their symptoms. The tool is not proprietary and can be used by entities that are not able to develop their own tracking systems.

Newswise: Support for telehealth and mobile health monitoring rises since COVID, study says
Released: 13-Aug-2020 11:25 AM EDT
Support for telehealth and mobile health monitoring rises since COVID, study says
University of Alabama Huntsville

Support for telehealth and mobile health monitoring has risen among healthcare workers and consumers since the rise of the COVID-19 pandemic, according to a new study. Dr. Emil Jovanov, a pioneer in the wearable health monitoring field from The University of Alabama in Huntsville (UAH), participated and was a coauthor.


Showing results

110 of 2911

close
2.58872